| Literature DB >> 34069935 |
Long-Hui Liang1,2, Yang Yang1,2, Shu Geng1, Xi Cheng2, Hui-Lan Yu1,2, Chang-Cai Liu1,2, Shi-Lei Liu1,2.
Abstract
The high toxic abrin from the plant Abrus precatorius is a type II ribosome-inactivating protein toxin with a human lethal dose of 0.1-1.0 µg/kg body weight. Due to its high toxicity and the potential misuse as a biothreat agent, it is of great importance to developing fast and reliable methods for the identification and quantification of abrin in complex matrices. Here, we report rapid and efficient acetonitrile (ACN)- and ultrasound-assisted on-bead trypsin digestion method combined with HPLC-MS/MS for the quantification of abrin isoforms in complex matrices. Specific peptides of abrin isoforms were generated by direct ACN-assisted trypsin digestion and analyzed by HPLC-HRMS. Combined with in silico digestion and BLASTp database search, fifteen marker peptides were selected for differential detection of abrin isoforms. The abrin in milk and plasma was enriched by immunomagnetic beads prepared by biotinylated anti-abrin polyclonal antibodies conjugated to streptavidin magnetic beads. The ultrasound-assisted on-bead trypsin digestion method was carried out under the condition of 10% ACN as denaturant solvent, the entire digestion time was further shortened from 90 min to 30 min. The four peptides of T3Aa,b,c,d, T12Aa, T15Ab, and T9Ac,d were chosen as quantification for total abrin, abrin-a, abrin-b, and abrin-c/d, respectively. The absolute quantification of abrin and its isoforms was accomplished by isotope dilution with labeled AQUA peptides and analyzed by HPLC-MS/MS (MRM). The developed method was fully validated in milk and plasma matrices with quantification limits in the range of 1.0-9.4 ng/mL for the isoforms of abrin. Furthermore, the developed approach was applied for the characterization of abrin isoforms from various fractions from gel filtration separation of the seeds, and measurement of abrin in the samples of biotoxin exercises organized by the Organization for the Prohibition of Chemical Weapons (OPCW). This study provided a recommended method for the differential identification of abrin isoforms, which are easily applied in international laboratories to improve the capabilities for the analysis of biotoxin samples.Entities:
Keywords: HPLC-ESI-MS/MS; RIP II protein toxins; detection of abrin; marker peptides; ultrasound-assisted trypsin digestion
Year: 2021 PMID: 34069935 PMCID: PMC8157574 DOI: 10.3390/toxins13050358
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1High-resolution liquid-mass extraction ion chromatograms of peptide markers from four isoforms of abrin. (a) High-resolution liquid-mass extraction ion chromatograms of peptide markers from abrin-a; (b) High-resolution liquid-mass extraction ion chromatograms of peptide markers from abrin-b; (c) High-resolution liquid-mass extraction ion chromatograms of peptide markers from abrin-c; (d) High-resolution liquid-mass extraction ion chromatograms of peptide markers from abrin-d.
Figure 2The influence of different denaturation conditions on the yields of abrin marker peptides (a) and the comparison of trypsin digestion protocols (b).
The optimized MRM parameters for the HPLC-MS/MS analysis of marker and IS peptides.
| Peptide | Amino Acid Sequences | Precursor Ion | Product Ions | Fragmentor | Collision Energy |
|---|---|---|---|---|---|
| T3Aa,b,c,d | QFIEALR | 438.9 (2+) | 601.4, 488.7, 429.6 | 90 | 15, 10, 8 |
| T2Aa | FSTEGATSQSYK | 653.4 (2+) | 841.4, 713.3, 527.3 | 170 | 20, 20, 20 |
| T6Aa | GGLIHDIPVLPDPTTLQER | 691.2 (3+) | 1015.5, 902.5, 844.4 | 120 | 15, 20, 25 |
| T9Aa | AGTQSYFLR | 521.8 (2+) | 685.4, 598.3, 512.8 | 120 | 20, 10, 10 |
| T12Aa | QQIPLGLQALTHGISFFR | 676.2 (3+) | 829.4, 670.2, 553.4 | 160 | 15, 15, 15 |
| T5Ab | LTGGLIHGIPVLPDPTTLQER | 743.2 (3+) | 862.5, 844.4, 528.8 | 120 | 25, 30, 15 |
| T15Ab | QQIPLGLQALR | 619.0 (2+) | 867.6, 610.0, 257.2 | 140 | 20, 15, 20 |
| T16Ab | HAISFLQSGTDDQEIAR | 630.2 (3+) | 1091.6, 556.4, 86.2 | 130 | 15, 20, 30 |
| T7Ac,d | YITVELSNSER | 656.0 (2+) | 1034.6, 834.5, 249.2 | 150 | 20, 20, 25 |
| T9Ac,d | AGSQSYFLR | 514.8 (2+) | 685.4, 505.8, 441.8 | 110 | 15, 10, 15 |
| T12Ac,d | FDGSYGDLER | 579.8 (2+) | 896.8, 752.4, 589.4 | 130 | 20, 20, 20 |
| T14Ac,d | EEISLGLQALTHAISFLR | 666.9 (3+) | 814.1, 770.6, 714.4 | 140 | 15, 15, 15 |
| T4Ba,b/T3Bc,d | YEPTVR | 382.8 (2+) | 472.3, 265.2, 236.7 | 90 | 8, 10, 8 |
| T10Ba,b/T9Bc,d | LEENQLWTLK | 637.4 (2+) | 361.2, 243.1, 215.1 | 160 | 20, 20, 25 |
| T19Ba,b/T18Bc/T17Bd | EQQWALYTDGSIR | 783.9 (2+) | 924.4, 811.4, 368.2 | 170 | 25, 25, 30 |
| T3Aa,b,c,d* | QFIEALR* | 443.9 (2+) | 611.4, 498.3, 434.6 | 90 | 15, 12, 8 |
| T12A a* | QQIPLGLQALTHGISFFR* | 679.5 (3+) | 834.0, 673.5, 556.4 | 150 | 18, 15, 15 |
| T15A b* | QQIPLGLQALR* | 624.0 (2+) | 877.5, 614.9, 439.3 | 120 | 35, 15, 15 |
| T9A c,d* | AGSQSYFLR* | 519.9 (2+) | 695.4, 510.9, 446.8 | 100 | 15, 812 |
R*: [13C6;15N4] labeled arginine.
Figure 3MRM chromatograms of all 15 abrin peptide markers.
Standard curve, linear range, limit of detection, and limit of quantification of different abrin isoforms in milk and plasma.
| Peptide | Matrices | Calibration Curve | R2 | LOD (ng/mL) | LOQ (ng/mL) | Range (ng/mL) |
|---|---|---|---|---|---|---|
| T3Aa,b,c,d | Milk | Y = 0.3103X + 1.4980 | 0.998 | 0.50 | 1.00 | 1.00–500 |
| T12Aa | Milk | Y = 0.0851X − 0.1942 | 0.998 | 0.47 | 2.35 | 2.35–235 |
| T15Ab | Milk | Y = 0.0041X + 0.2192 | 0.996 | 1.71 | 3.42 | 3.42–513 |
| T9Ac,d | Milk | Y = 0.0041X + 0.4499 | 0.998 | 5.64 | 9.40 | 9.40–376 |
| T3Aa,b,c,d | Plasma | Y = 0.037X + 1.6101 | 0.999 | 0.50 | 1.00 | 1.00–500 |
| T12Aa | Plasma | Y = 0.0879X + 0.4292 | 0.999 | 0.47 | 2.35 | 2.35–235 |
| T15Ab | Plasma | Y = 0.0045X + 0.2651 | 0.996 | 1.71 | 3.42 | 3.42–513 |
| T9Ac,d | Plasma | Y = 0.0045X + 0.4597 | 0.995 | 5.64 | 9.40 | 9.40–376 |
Intra/Inter-day accuracy and precision (RSD%) over all QC samples.
| Sample | Quantitative Peptides | Matrices | Spiking Concentration (ng/mL) | Intra-Day ( | Inter-Day ( | ||||
|---|---|---|---|---|---|---|---|---|---|
| Calculated | Accuracy | RSD | Calculated | Accuracy | RSD | ||||
| QCL | T3Aa,b,c,d | Milk | 10.0 (total abrin) | 9.76 ± 0.14 | 97.6 | 6.3 | 9.45 ± 0.19 | 94.5 | 11.4 |
| QCL | T12Aa | Milk | 4.70 (abrin-a) | 4.38 ± 0.04 | 94.7 | 8.8 | 4.07 ± 0.10 | 86.5 | 7.5 |
| QCL | T15Ab | Milk | 3.42 (abrin-b) | 3.67 ± 0.02 | 107.4 | 7.6 | 3.18 ± 0.16 | 93.1 | 7.8 |
| QCL | T9Ac,d | Milk | 1.88 (abrin-c/d) | - | - | - | - | - | - |
| QCM | T3Aa,b,c,d | Milk | 150 (total abrin) | 150.2 ± 3.90 | 100.1 | 3.7 | 142.0 ± 0.81 | 94.7 | 9.2 |
| QCM | T12Aa | Milk | 70.5 (abrin-a) | 67.4 ± 0.02 | 95.6 | 3.3 | 64.9 ± 0.11 | 92.1 | 8.2 |
| QCM | T15Ab | Milk | 51.3 (abrin-b) | 48.5 ± 1.04 | 94.6 | 2.7 | 46.1 ± 0.15 | 88.9 | 6.9 |
| QCM | T9Ac,d | Milk | 28.2 (abrin-c/d) | 24.4 ± 0.04 | 86.7 | 2.9 | 24.3 ± 0.08 | 86.1 | 4.9 |
| QCH | T3Aa,b,c,d | Milk | 300 (total abrin) | 288.0 ± 0.18 | 96.0 | 1.7 | 279.5 ± 8.71 | 93.2 | 5.5 |
| QCH | T12Aa | Milk | 141 (abrin-a) | 129.9 ± 0.95 | 92.1 | 2.9 | 123.1 ± 6.32 | 87.3 | 5.3 |
| QCH | T15Ab | Milk | 102.6 (abrin-b) | 97.8 ± 1.23 | 95.3 | 2.2 | 92.1 ± 4.83 | 89.8 | 2.9 |
| QCH | T9Ac,d | Milk | 56.4 (abrin-c/d) | 49.2 ± 1.74 | 87.2 | 3.8 | 47.1 ± 5.71 | 83.5 | 4.5 |
| QCL | T3Aa,b,c,d | Plasma | 10.0 (total abrin) | 11.2 ± 0.18 | 112.0 | 8.5 | 10.9 ± 0.23 | 109.0 | 9.9 |
| QCL | T12Aa | Plasma | 4.70 (abrin-a) | 6.88 ± 1.01 | 102.7 | 5.3 | 6.32 ± 0.88 | 94.0 | 8.8 |
| QCL | T15Ab | Plasma | 3.42 (abrin-b) | 3.02 ± 0.53 | 111.1 | 4.9 | 2.50 ± 0.58 | 92.9 | 11.3 |
| QCL | T9Ac,d | Plasma | 1.88 (abrin-c/d) | - | - | - | - | - | - |
| QCM | T3Aa,b,c,d | Plasma | 150 (total abrin) | 148.6 ± 3.3 | 99.1 | 3.2 | 142.6 ± 4.8 | 94.9 | 6.9 |
| QCM | T12Aa | Plasma | 70.5 (abrin-a) | 67.8 ± 5.6 | 96.2 | 4.8 | 64.9 ± 4.6 | 92.0 | 8.6 |
| QCM | T15Ab | Plasma | 51.3 (abrin-b) | 48.9 ± 1.8 | 95.3 | 2.9 | 42.6 ± 2.1 | 83.0 | 6.2 |
| QCM | T9Ac,d | Plasma | 28.2 (abrin-c/d) | 24.3 ± 0.8 | 86.2 | 5.6 | 24.9 ± 1.9 | 88.3 | 8.9 |
| QCH | T3Aa,b,c,d | Plasma | 300 (total abrin) | 293.3 ± 1.92 | 97.8 | 1.8 | 289.5 ± 2.3 | 96.5 | 4.4 |
| QCH | T12Aa | Plasma | 141 (abrin-a) | 132.4 ± 4.13 | 93.9 | 1.7 | 126.1 ± 5.3 | 89.4 | 5.3 |
| QCH | T15Ab | Plasma | 102.6 (abrin-b) | 98.7 ± 3.2 | 96.2 | 2.8 | 94.7 ± 3.3 | 92.3 | 5.9 |
| QCH | T9Ac,d | Plasma | 56.4 (abrin-c/d) | 53.2 ± 1.2 | 94.3 | 6.1 | 51.8 ± 2.5 | 91.8 | 8.6 |
Immunocapture extraction recovery of abrin in milk and plasma.
| Sample ID | Spiking Concentration | Matrices | Extraction Recovery % | RSD % |
|---|---|---|---|---|
| QCL | 10.0 | Milk | 76.3 | 3.3 |
| QCM | 150 | Milk | 77.4 | 2.1 |
| QCH | 300 | Milk | 71.1 | 1.8 |
| QCL | 10.0 | Plasma | 80.9 | 4.9 |
| QCM | 150 | Plasma | 77.8 | 2.8 |
| QCH | 300 | Plasma | 73.4 | 1.2 |
Matrix effects of abrin peptide markers in milk and plasma.
| Sample ID | Matrices | Spiking Concertation of Peptides (ng/mL) | Matrices Effect of T3Aa,b,c,d % | Matrix Effect of T12Aa % | Matrix Effect of T15Ab % | Matrix Effect of T9Ac,d % |
|---|---|---|---|---|---|---|
| QC-L | Milk | 2.00 | 128.8 ± 2.8 | 110.8 ± 3.7 | 124.2 ± 5.6 | 106.9 ± 3.3 |
| QC-M | Milk | 20.0 | 106.2 ± 4.2 | 96.1 ± 4.1 | 96.5 ± 4.8 | 91.5 ± 2.8 |
| QC-H | Milk | 100 | 103.3 ± 1.1 | 94.3 ± 6.2 | 96.9 ± 3.1 | 102.7 ± 2.6 |
| QC-L | Plasma | 2.00 | 112.5 ± 2.6 | 113.0 ± 2.9 | 125.9 ± 2.5 | 110.9 ± 3.4 |
| QC-M | Plasma | 20.0 | 112.7 ± 3.6 | 97.3 ± 4.5 | 108.5 ± 2.6 | 98.1 ± 5.6 |
| QC-H | Plasma | 100 | 91.9 ± 2.9 | 92.8 ± 2.3 | 98.6 ± 3.7 | 96.5 ± 2.7 |
Figure 4The investigation of sample stability. (a) The stability of the processed QC samples at 4 °C, room temperature and 37 °C for one week; (b) the stability of the QC samples after 5 times freeze-thaw cycles.
The analysis results of the biotoxin sample analysis exercise.
| Sample | Spiking Chemicals/(Nominal Concentration) | Matrices | Identification | Identified |
|---|---|---|---|---|
| A172.1 | Blank | BSA 1 mg/mL in 5% AcOH | - | |
| A172.4 | Purified abrin (100 μg/mL) | BSA 1 mg/mL in 5% AcOH | Abrin | 15 (12 from A chain and 3 from B chain) |
| A172.5 | Purified ricin (100 μg/g) | Commercial Stevia powder | Abrin | 15 (12 from A chain and 3 from B chain) |
| BT18.1 | Purified * Abrin (150 μg/g) | Protein powder | Abrin | 11 (8 from A chain and 3 from B chain) |
| BT18.2 | Abrus Agglutinin * (300 μg/g) | Protein powder | Abrin | 11 (8 from A chain and 3 from B chain) |
| BT18.4 | Blank | Protein powder | - | |
| BT18.7 | Blank | Saline solution | - | |
| BT19.1 | Blank (Contains BSA) | SDS-PAGE gel * | ||
| BT19.3 | Crude Castor Bean Extract (15 μg/spot) | SDS-PAGE gel | Abrin | 9 (6 from A chain and 3 from B chain) |
| BT19.5 | Blank | Spray buffer † | - |
* SDS-PAGE gel spot size was standardized by using a gel cutting tip. Gel pieces were dried before storage and shipping. † Spray buffer consists of PBST buffer (1000 mL), Polypropylene glycol monobutylether (120 mL), PEG200 (60 mL), Glycerol (50 mL), ethanol (100 mL) and isopropanol (100 mL). In the second biotoxin exercise, four aqueous samples (A172.1–A172.4, prepared in 1 mg/mL of BSA in 5% AcOH) and three solid samples (A172.5–A172.7, prepared in Stevia powder) were provided by the OPCW center laboratory. For solid samples, three to ten volumes of 2% acetic acid were used to extracted abrin from Stevia powder. In the third biotoxin exercise, five powder samples (BT18.1-BT18.5, prepared in protein powder) and two aqueous samples (BT18.6 and BT18.7, prepared in saline solution). In the fourth biotoxin exercise, three SDS-PAGE gel samples (BT19.1–BT18.3) and four aqueous samples (BT18.6 and BT18.7, prepared in spray buffer) were provided by the OPCW center laboratory.